☰

Traci R. Tuttle, Ph.D. - Publications

Affiliations: 
2013 Cell and Molecular Biology University of Cincinnati, Cincinnati, OH 
Area:
Molecular Biology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

7 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Tuttle TR, Takiar V, Kumar B, Kumar P, Ben-Jonathan N. Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells. Cancer Letters. PMID 28025101 DOI: 10.1016/J.Canlet.2016.12.020  0.568
2015 Tuttle TR, Mierzwa ML, Wells SI, Fox SR, Ben-Jonathan N. The cyclic GMP/protein kinase g pathway as a therapeutic target in head and neck squamous cell carcinoma. Cancer Letters. PMID 26551887 DOI: 10.1016/J.Canlet.2015.10.024  0.579
2014 Tuttle TR, Hugo ER, Tong WS, Ben-Jonathan N. Placental lactogen is expressed but is not translated into protein in breast cancer. Plos One. 9: e87325. PMID 24475273 DOI: 10.1371/Journal.Pone.0087325  0.616
2014 Tuttle T, Tong W, Casper K, Mierzwa M, Ben-Jonathan N. Expression and Therapeutic Applications of Dopamine Receptors in Head-and-Neck Cancer International Journal of Radiation Oncology*Biology*Physics. 88: 517. DOI: 10.1016/J.Ijrobp.2013.11.168  0.586
2011 Idelman G, Jacobson EM, Tuttle TR, Ben-Jonathan N. Lactogens and estrogens in breast cancer chemoresistance. Expert Review of Endocrinology & Metabolism. 6: 411-422. PMID 21731573 DOI: 10.1586/Eem.11.19  0.67
2010 Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends in Endocrinology and Metabolism: Tem. 21: 691-8. PMID 20846877 DOI: 10.1016/J.Tem.2010.08.004  0.625
2009 Lapensee EW, Tuttle TR, Fox SR, Ben-Jonathan N. Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells. Environmental Health Perspectives. 117: 175-80. PMID 19270784 DOI: 10.1289/Ehp.11788  0.537
Show low-probability matches.